Mark Sulkowski, MD

Description

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Department of Medicine at Johns Hopkins Bayview Medical Center.  He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA, pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC, and completed his Fellowship in Infectious Diseases at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 275 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection.  He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus.   He is an elected member of the American Society for Clinical Investigation and the American Association of Physicians. Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA).  With more than 350 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology.  From 2017 to 2022, he was named a Highly Cited Researcher (Clarivate Analytics), defined as being in the top 1% of global researchers across 21 fields of the sciences and social sciences, based on the number of citations to his papers.  As an invited lecturer, he has frequently presented at major national and international medical congresses and has educated learners in more than 25 countries.